{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T16:11:10Z","timestamp":1779120670728,"version":"3.51.4"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to improve clinical outcomes for patients with type 2 diabetes and chronic kidney disease (CKD), yet their uptake in clinical practice remains low.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess whether pharmacist-led outreach would be associated with increased initiation of SGLT2 inhibitor use among patients with type 2 diabetes and CKD.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n In this quality improvement study, eligible patients identified through an established Veterans Affairs (VA) diabetes dashboard were divided into 2 groups based on the last digit of their Social Security number, creating a pseudorandomized treatment assignment. The study was conducted from February 2022 through April 2024 in 8 VA health systems in the midwestern US. Veterans with CKD (estimated glomerular filtration rate \u226525 and &amp;lt;60 mL\/min\/1.73 m\n 2<\/jats:sup>\n ) and type 2 diabetes were included. Patients were excluded if they were already prescribed an SGLT2 inhibitor or had an SGLT2 inhibitor allergy, type 1 diabetes, or contraindicating conditions.\n <\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Eligible patients in the intervention group were mailed a letter describing the benefits of SGLT2 inhibitors. Patients were then scheduled for a 30-minute telephone visit with a pharmacist. Patients determined to be a candidate for the medication were prescribed empagliflozin. The usual care group received no targeted outreach but could be prescribed the medication during the natural course of care.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was initiation of an SGLT2 inhibitor, determined by prescription fill, at any point during the study. The secondary outcome was SGLT2 inhibitor prescription fill at 12 months. The exploratory outcomes, assessed by win ratio analysis, included a composite of time to all-cause mortality, kidney failure, heart failure, myocardial infarction, and stroke along with each of these outcomes individually. Longer time to event for the intervention than the control group was considered a win.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 8658 eligible patients (mean [SD] age, 78.7 [8.1] years; 8368 [96.7%] male; 76 [0.9%] American Indian or Alaska Native, 11 [0.1%] Asian, 327 [3.8%] Black, 44 [0.5%] Pacific Islander, 7435 [85.9%] White, and 765 [8.8%] with unknown or unreported race), 4400 (50.8%) were assigned to the pharmacist intervention and 4258 (49.2%) to usual care. The cumulative proportion of SGLT2 inhibitor prescriptions filled 1 year after group assignment was 1476 (33.5%) for the intervention group compared with 659 (15.5%) for control. At 12 months, 864 intervention patients (19.6%) filled a prescription for an SGLT2 inhibitor compared with 415 (9.7%) in the control group. The hazard ratio for initiation of an SGLT2 inhibitor in the intervention vs control group was 1.91 (95% CI, 1.69-2.16;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). No significant difference was observed in the composite clinical outcome (win ratio, 1.02; 95% CI, 0.97-1.07;\n P<\/jats:italic>\n \u2009=\u2009.54).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this quality improvement study, pharmacist-led outreach was associated with increased initiation of SGLT2 inhibitors; however, limited intervention reach may have constrained the overall impact. Strategies to improve uptake are needed to enhance impact and inform broader SGLT2 inhibitor implementation in patients with CKD and type 2 diabetes.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.13081","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:30:31Z","timestamp":1779118231000},"page":"e2613081","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacist Outreach and SGLT2 Inhibitor Uptake in Patients With Diabetes and Chronic Kidney Disease"],"prefix":"10.1001","volume":"9","author":[{"given":"Deborah L.","family":"Pestka","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Minnesota, Minneapolis"},{"name":"Minneapolis VA Health Care System, Minneapolis, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Murphy","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Minnesota, Minneapolis"},{"name":"Minneapolis VA Health Care System, Minneapolis, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam N.","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Minneapolis VA Health Care System, Minneapolis, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent C.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Minnesota, Minneapolis"},{"name":"Minneapolis VA Health Care System, Minneapolis, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pearl","family":"Huynh","sequence":"additional","affiliation":[{"name":"Minneapolis VA Health Care System, Minneapolis, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica A.","family":"Rechtzigel","sequence":"additional","affiliation":[{"name":"Minneapolis VA Health Care System, Minneapolis, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shari","family":"Kjos","sequence":"additional","affiliation":[{"name":"Minneapolis VA Health Care System, Minneapolis, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa Marie","family":"Ellich","sequence":"additional","affiliation":[{"name":"Minneapolis VA Health Care System, Minneapolis, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Atwood","sequence":"additional","affiliation":[{"name":"Minneapolis VA Health Care System, Minneapolis, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth A.","family":"Polsfuss","sequence":"additional","affiliation":[{"name":"Minneapolis VA Health Care System, Minneapolis, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amber R.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Fargo VA Health Care System, Fargo, North Dakota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph Y.","family":"Lee","sequence":"additional","affiliation":[{"name":"Minneapolis VA Health Care System, Minneapolis, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Areef","family":"Ishani","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Minnesota, Minneapolis"},{"name":"Minneapolis VA Health Care System, Minneapolis, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"issue":"13","key":"zoi260391r2","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi260391r5","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1007\/s12325-023-02608-9","article-title":"Global economic burden associated with chronic kidney disease: a pragmatic review of medical costs for the Inside CKD Research Programme.","volume":"40","author":"Jha","year":"2023","journal-title":"Adv Ther"},{"issue":"10225","key":"zoi260391r6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.","volume":"395","author":"Bikbov","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"zoi260391r7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease.","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"zoi260391r8","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"zoi260391r9","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi260391r10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease.","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi260391r11","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/HYPERTENSIONAHA.119.11684","article-title":"Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors.","volume":"75","author":"Wilcox","year":"2020","journal-title":"Hypertension"},{"issue":"9","key":"zoi260391r12","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"zoi260391r13","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.2337\/dc25-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142025.","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"issue":"5","key":"zoi260391r14","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","article-title":"Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence.","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int"},{"issue":"12","key":"zoi260391r15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.121.008381","article-title":"Patterns of prescribing sodium-glucose cotransporter-2 inhibitors for Medicare beneficiaries in the United States.","volume":"14","author":"Sangha","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"zoi260391r16","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.1031306","article-title":"The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: a two-center retrospective cross-sectional study.","volume":"10","author":"Korayem","year":"2022","journal-title":"Front Public Health"},{"issue":"1","key":"zoi260391r17","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s12872-024-03961-5","article-title":"Prescribing trends of SGLT2 inhibitors among HFrEF and HFpEF patients with and without T2DM, 2013-2021.","volume":"24","author":"Gonzalez","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"issue":"8","key":"zoi260391r18","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.jacc.2024.05.057","article-title":"Prescription patterns for sodium-glucose cotransporter 2 inhibitors in US health systems.","volume":"84","author":"Shin","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"zoi260391r20","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3102\/0002831218761337","article-title":"Food instability and academic achievement: a quasi-experiment using SNAP benefit timing.","volume":"55","author":"Gassman-Pines","year":"2018","journal-title":"Am Educ Res J"},{"issue":"3","key":"zoi260391r21","first-page":"158","article-title":"An intervention for VA patients with congestive heart failure.","volume":"16","author":"Copeland","year":"2010","journal-title":"Am J Manag Care"},{"issue":"1","key":"zoi260391r22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12882-023-03446-1","article-title":"Pharmacist-driven outreach initiative to increase prescribing of sodium-glucose cotransporter-2 inhibitors in eligible VHA patients with chronic kidney disease: a study protocol.","volume":"25","author":"Pestka","year":"2024","journal-title":"BMC Nephrol"},{"issue":"12","key":"zoi260391r23","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1136\/bmjqs-2015-004411","article-title":"SQUIRE 2.0 (Standards for Quality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process.","volume":"25","author":"Ogrinc","year":"2016","journal-title":"BMJ Qual Saf"},{"issue":"4","key":"zoi260391r24","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/MLR.0b013e31827da95a","article-title":"Predicting risk of hospitalization or death among patients receiving primary care in the Veterans Health Administration.","volume":"51","author":"Wang","year":"2013","journal-title":"Med Care"},{"issue":"5","key":"zoi260391r25","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1177\/17407745241259356","article-title":"Defining estimand for the win ratio: separate the true effect from censoring.","volume":"21","author":"Mao","year":"2024","journal-title":"Clin Trials"},{"issue":"46","key":"zoi260391r26","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1093\/eurheartj\/ehaa665","article-title":"The win ratio approach for composite endpoints: practical guidance based on previous experience.","volume":"41","author":"Redfors","year":"2020","journal-title":"Eur Heart J"},{"issue":"44","key":"zoi260391r27","doi-asserted-by":"publisher","first-page":"4684","DOI":"10.1093\/eurheartj\/ehae647","article-title":"The win ratio in cardiology trials: lessons learnt, new developments, and wise future use.","volume":"45","author":"Pocock","year":"2024","journal-title":"Eur Heart J"},{"issue":"15-17","key":"zoi260391r28","doi-asserted-by":"publisher","DOI":"10.1002\/sim.70180","article-title":"An IPCW adjusted win statistics approach in clinical trials incorporating equivalence margins to define ties.","volume":"44","author":"Cui","year":"2025","journal-title":"Stat Med"},{"issue":"12","key":"zoi260391r30","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.18553\/jmcp.2023.29.12.1275","article-title":"Pharmacist impact on evidence-based prescribing of diabetes medications in patients with clinical atherosclerotic cardiovascular disease.","volume":"29","author":"Trueman","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"zoi260391r31","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2025.102399","article-title":"The impact of a pharmacist-led comprehensive diabetes management program in a federally qualified health center.","volume":"65","author":"Rochester-Eyeguokan","year":"2025","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"5","key":"zoi260391r32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.pcd.2019.12.007","article-title":"The impact of pharmacist care on diabetes outcomes in primary care settings: an umbrella review of published systematic reviews.","volume":"14","author":"Abdulrhim","year":"2020","journal-title":"Prim Care Diabetes"},{"issue":"2","key":"zoi260391r33","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000718","article-title":"Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials.","volume":"3","author":"Santschi","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"zoi260391r34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11897-017-0323-2","article-title":"Role of the pharmacist for improving self-care and outcomes in heart failure.","volume":"14","author":"Parajuli","year":"2017","journal-title":"Curr Heart Fail Rep"},{"issue":"7","key":"zoi260391r35","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/archinte.168.7.687","article-title":"Pharmacist care of patients with heart failure: a systematic review of randomized trials.","volume":"168","author":"Koshman","year":"2008","journal-title":"Arch Intern Med"},{"key":"zoi260391r36","doi-asserted-by":"publisher","DOI":"10.1177\/20543581231217857","article-title":"Identifying barriers and facilitators for increasing uptake of sodium-glucose cotransporter-2 (SGLT2) inhibitors in British Columbia, Canada, using the Consolidated Framework for Implementation Research.","author":"Yi","journal-title":"Can J Kidney Health Dis"},{"issue":"1","key":"zoi260391r37","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11606-022-07707-x","article-title":"Revisiting the time needed to provide adult primary care.","volume":"38","author":"Porter","year":"2023","journal-title":"J Gen Intern Med"},{"issue":"10365","key":"zoi260391r38","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"zoi260391r39","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes.","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"zoi260391r40","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi260391r41","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi260391r42","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1097\/00004583-200006000-00020","article-title":"Quasi-experimental designs.","volume":"39","author":"Morgan","year":"2000","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"zoi260391r1","unstructured":"Centers for Disease Control and Prevention. Chronic kidney disease in the United States. March 31, 2026. Accessed July 30, 2025. https:\/\/www.cdc.gov\/kidney-disease\/php\/data-research\/index.html"},{"key":"zoi260391r3","unstructured":"US Renal Data System. 2025 Annual data report. National Institute of Diabetes and Digestive and Kidney Diseases. Accessed July 30, 2025. https:\/\/usrds-adr.niddk.nih.gov\/"},{"key":"zoi260391r4","unstructured":"Centers for Disease Control and Prevention. Chronic kidney disease: common, serious, and costly. May 15, 2024. Accessed July 30, 2025. https:\/\/www.cdc.gov\/kidney-disease\/ckd-facts\/index.html"},{"key":"zoi260391r19","unstructured":"Kestenbaum? B. Consequences of social security number randomization. Accessed November 26, 2025. https:\/\/nces.ed.gov\/FCSM\/pdf\/Kestenbaum_2012FCSM_VII-C.pdf"},{"key":"zoi260391r29","unstructured":"R: A Language and Environment for Statistical Computing. Version 4.5.1. R Project for Statistical Computing; 2024. Accessed April 1, 2026. https:\/\/www.R-project.org\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2849119\/pestka_2026_oi_260391_1778512974.91312.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:30:40Z","timestamp":1779118240000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2849119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.13081","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]}}}